Search results
Results from the WOW.Com Content Network
A large-scale study in Buenos Aires from December 29, 2020, to May 15, 2021, with 663,602 participants aged 60 and older who received Spunik V, the Oxford–AstraZeneca vaccine, or the Sinopharm BIBP vaccine observed an overall efficacy of 98% (95% CI, 95 – 99%) against COVID-19-related deaths. The study noted that the three vaccines showed a ...
Moderna has launched a trial of a vaccine to tackle the Beta variant or lineage B.1.351. [460] On 17 February 2021, Pfizer announced neutralization activity was reduced by two-thirds for this variant, while stating that no claims about the efficacy of the vaccine in preventing illness for this variant could yet be made. [461]
English: Sputnik V efficacy for different conditions. Data from: Logunov D. Y. et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia.
Vaccine Initial effectiveness by severity of COVID-19 Study location Refs Asymptomatic Symptomatic Hospitalization Death Oxford–AstraZeneca
(Reuters) -Moderna said on Thursday its next-generation COVID-19 vaccine candidate showed it was not inferior in efficacy compared to its approved shot in a late-stage study. The experimental ...
Retrospective cohort study of the effectiveness of two Russian vaccines against the SARS-CoV-2 Delta variant in Moscow (June–July 2021) proved that EpiVacCorona, unlike Sputnik V, is an ineffective vaccine and therefore cannot protect against COVID-19. [4]
Moderna fell as much as 7% on Friday after Wall Street analysts raised concerns over faster declines in the efficacy of its experimental respiratory syncytial virus (RSV) vaccine when compared ...
The vaccine, designed to train the immune system of patients to recognize and attack specific mutations in cancer cells, earlier showed promise in treating melanoma in a mid-stage study. "The data ...